Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
ACS Applied Bio Materials|January 8, 2022
Aptamer-Conjugated Apigenin Nanoparticles To Target Colorectal Carcinoma: A Promising Safe Alternative of Colorectal Cancer ChemotherapyDebasmita Dutta, Apala Chakraborty, Biswajit Mukherjee, et al.
Metabolic Brain Disease|February 27, 2021
Metabolic disorder in Alzheimer's diseaseMrinal K Poddar, Soumyabrata Banerjee, Apala Chakraborty, et al.
BMC Cancer|January 17, 2016
A potent betulinic acid analogue ascertains an antagonistic mechanism between autophagy and proteasomal degradation pathway in HT-29 cellsDebasmita Dutta, Biswajit Chakraborty, Ankita Sarkar, et al.
Bioelectricity|August 29, 2020
Functional Applications of Polyarginine-Hyaluronic Acid-Based Electrostatic ComplexesNarendra R Kale, Debasmita Dutta, William Carstens, et al.
Expert Opinion on Drug Delivery|March 10, 2025
Molecular insights into the antineoplastic potential of apigenin and its derivatives: paving the way for nanotherapeutic innovationsDebasmita Dutta, Ashique Al Hoque, Brahamacharry Paul, et al.
Journal of Nanobiotechnology|January 24, 2023
Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approachMoumita Dhara, Ashique Al Hoque, Ramkrishna Sen, et al.
Scientific Reports|August 10, 2019
Nanoencapsulated betulinic acid analogue distinctively improves colorectal carcinoma in vitro and in vivoDebasmita Dutta, Brahamacharry Paul, Biswajit Mukherjee, et al.
European Journal of Medicinal Chemistry|August 7, 2015
Synthesis and biological evaluation of a novel betulinic acid derivative as an inducer of apoptosis in human colon carcinoma cells (HT-29)Biswajit Chakraborty, Debasmita Dutta, Sanjukta Mukherjee, et al.
Biomaterials Advances|May 17, 2022
Inhibitory potential of iRGD peptide-conjugated garcinol-loaded biodegradable nanoparticles in rat colorectal carcinomaBrahamacharry Paul, Raghuvir H Gaonkar, Debasmita Dutta, et al.
Blood Cancer Journal|December 10, 2023
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.
Pageof 3